前立腺癌に対するEstracytの臨床効果

Abstract

The clinical effects of Estracyt(R) on prostatic cancer were evaluated in seventeen patients. Nine patients of them were given Estracyt(R) as primary treatment (group I) and the others had been previously treated with antiandrogen treatment with unsatisfactory results (group II). The clinical effects were judged from the improvement of objective and/or subjective symptoms at the end of three months administration. The clinical responses were observed in 8 (89%) of the 9 patients in group I, and 5 (63%) of the 8 patients in group II. But, 5 of 8 patients in group I who had showed clinical responses suffered relapses in the following treatment with Estracy(R) and died within one year. Although the oral administration of Estracyt(R) is valuable in the treatment of prostatic cancer, some patients may have a relapse. Therefore, the careful follow-up is recommended and when any sign of relapse is observed the radical operative procedure must be applied immediately.